title: Primary human papillomavirus screening for cervical cancer in the United States-US Food and Drug Administration approval, clinical trials, and where we are today.
authors.affiliation: Division of Cytopathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
authors.forename: Ritu
authors.initials: R
authors.lastname: Nayar
authors.forename: Robert A
authors.initials: RA
authors.lastname: Goulart
authors.forename: Patricia G
authors.initials: PG
authors.lastname: Tiscornia-Wasserman
authors.forename: Diane Davis
authors.initials: DD
authors.lastname: Davey
mesh_terms: D000293:Adolescent; D000328:Adult; D001707:Biopsy, Needle; D002986:Clinical Trials as Topic; D003127:Colposcopy / Q000379:methods; D003581:Cytodiagnosis / Q000379:methods; D055088:Early Detection of Cancer / Q000379:methods* / Q000639:trends; D005188:False Negative Reactions; D005260:Female; D005544:Forecasting; D006801:Humans; D015994:Incidence; D008403:Mass Screening; D008875:Middle Aged; D020380:Needs Assessment; D065006:Papanicolaou Test; D030361:Papillomavirus Infections / Q000175:diagnosis*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D014481:United States; D014486:United States Food and Drug Administration; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000821:virology; D055815:Young Adult